Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
A phase 3 trial of Pimicotinib(ABSK021) in tenosynovial giant cell tumour, run by Abbisko Therapeutics Co, Ltd, active and no longer recruiting.
Overview
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER) is a phase 3 interventional study registered as NCT05804045 by Abbisko Therapeutics Co, Ltd, with 94 participants enrolled, started 2023-04-27 and due to reach its primary completion in 2024-09-23. Interventions recorded: Pimicotinib(ABSK021) and Placebo. Results have been posted on the registry.
Similar pages
not linked directly; found by shared links- TrialA Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
Shares Abbisko Therapeutics and the tag pipeline.
- TrialA Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )
Shares Abbisko Therapeutics and the tag pipeline.
- TrialA Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer
Shares Abbisko Therapeutics and the tag pipeline.
- TrialABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
Shares Abbisko Therapeutics and the tag pipeline.
- TrialA Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT
Shares Tenosynovial giant cell tumour (TGCT) and the tag pipeline.
- TrialStudy of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)
Shares Tenosynovial giant cell tumour (TGCT) and the tag pipeline.
- TreatmentEmactuzumab
Shares Tenosynovial giant cell tumour (TGCT) and the tag pipeline.
- TreatmentPimicotinib
Shares Tenosynovial giant cell tumour (TGCT) and the tag pipeline.